- Home
- PMVP vs CUE Comparison
PMVP vs CUE Comparison
Compare PMVP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- CUE
- Stock Information
- Founded
- PMVP 2013
- CUE 2014
- Country
- PMVP United States
- CUE United States
- Employees
- PMVP N/A
- CUE N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- CUE Health Care
- Exchange
- PMVP Nasdaq
- CUE Nasdaq
- Market Cap
- PMVP 85.5M
- CUE 91.9M
- IPO Year
- PMVP 2020
- CUE 2018
- Fundamental
- Price
- PMVP $1.43
- CUE $1.28
- Analyst Decision
- PMVP Strong Buy
- CUE Strong Buy
- Analyst Count
- PMVP 3
- CUE 5
- Target Price
- PMVP $5.33
- CUE $5.00
- AVG Volume (30 Days)
- PMVP 158.0K
- CUE 283.2K
- Earning Date
- PMVP 02-27-2025
- CUE 03-10-2025
- Dividend Yield
- PMVP N/A
- CUE N/A
- EPS Growth
- PMVP N/A
- CUE N/A
- EPS
- PMVP N/A
- CUE N/A
- Revenue
- PMVP N/A
- CUE $9,532,000.00
- Revenue This Year
- PMVP N/A
- CUE $73.11
- Revenue Next Year
- PMVP N/A
- CUE $11.02
- P/E Ratio
- PMVP N/A
- CUE N/A
- Revenue Growth
- PMVP N/A
- CUE 149.53
- 52 Week Low
- PMVP $1.32
- CUE $0.45
- 52 Week High
- PMVP $2.26
- CUE $2.58
- Technical
- Relative Strength Index (RSI)
- PMVP 47.66
- CUE 46.30
- Support Level
- PMVP $1.37
- CUE $1.20
- Resistance Level
- PMVP $1.46
- CUE $1.50
- Average True Range (ATR)
- PMVP 0.05
- CUE 0.12
- MACD
- PMVP 0.01
- CUE -0.02
- Stochastic Oscillator
- PMVP 78.57
- CUE 38.30
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.